Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals Inc is a Delaware corporation formed in 2002. The Company along with its subsidiaries is a development-stage biopharmaceutical company engaged in developing minimally invasive products for the treatment of psoriasis and other topical diseases, and certain forms of cancer including melanoma, breast cancer, and cancers of the liver. To date, the Company has no revenues from planned principal operations. It is developing its prescription drug candidates PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema. It holds a number of U.S. patents covering the technologies it has developed and is continuing to develop for the production of prescription drugs, non-core technologies and OTC pharmaceuticals. The Company complies with all the regulations prescribed by FDA prior to sales within the United States and by comparable foreign agencies prior to sales outside the United States.